Información del artículo
El Texto completo está disponible en PDF
References
[1.]
Beninati C., Oggioni M.R., Boccanera M., Spinosa M.R., Maggi T., Conti S., Magliani W., De Bernardis F., Teti G., Cassone A., Pozzi G., Polonelli L..
Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria.
Nat Biotechnol, 18 (2000), pp. 1060-1064
[2.]
Delgado W., Aguirre J.M..
Las micosis orales en la era del sida.
Rev Iberoam Micol, 14 (1997), pp. 14-22
[3.]
Martins M., Lozano-Chiu M., Rex J.H..
Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C.
albicans in human immunodefficiency virus-infected patients. Clin Infect Dis, 27 (1998), pp. 1291-1294
[4.]
Mewes H.W., Albermann K., Bähr M., Frishman D., Gleissner A., Hani J., Heumann K., Kleine K., Maierl A., Oliver S.G., Pfeiffer F., Zollner A..
Overview of the yeast genome.
Nature, 387 (1997), pp. 7-8
[5.]
Sanglard D..
Integrated antifungal drug discovery in Candida albicans.
Nat Biotechnol, 19 (2001), pp. 212-213
[6.]
Sullivan D.J., Moran G..
Donnelly S, Gee S,.
Pinjon E,. McCartan B, Shanley DB, Coleman DC. Candida dubliniensis: an update. Rev Iberoam Micol, 16 (1999), pp. 72-76
[7.]
Cutler J.E..
Putative virulence factors of Candida albicans.
Annu Rev Microbiol, 45 (1991), pp. 187-218
[8.]
Hogan L., Klein B.S., Levitz S.M..
Virulence of medically important fungi.
Clin Microbiol Rev, 9 (1996), pp. 469-488
[9.]
Ogra P.l., Faden H., Welliver R.C..
Vaccination strategies for mucosal immune responses.
Clin Microbiol Rev, 14 (2001), pp. 430-445
Copyright © 2001. Academia de Ciencias Médicas de Bilbao